Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Antibody drug conjugates in recurrent or metastatic cervical cancer: a focus on tisotumab vedotin state of art.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Author(s): Camarda, Floriana; Paderno, Mariachiara; Cannizzaro, Maria Chiara; Nero, Camilla; Sabatucci, Ilaria; Fucà, Giovanni; Musacchio, Lucia; Salutari, Vanda; Scambia, Giovanni; Lorusso, Domenica
- Source:
Therapeutic Advances in Medical Oncology; 9/22/2024, p1-14, 14p
- Additional Information
- Abstract:
Cervical cancer (CC) is still characterized by a poor prognosis despite the progress made in its treatment in recent years. Although immunotherapy has improved outcomes for advanced/recurrent disease, there is a significant gap in addressing patients' needs when they progress after platinum and immunotherapy treatments. In this setting, traditional chemotherapy showed limited effectiveness. In this context, antibody–drug conjugates (ADCs) emerged as a promising tool within targeted cancer therapies. Tisotumab vedotin (TV), an ADC targeting tissue factor, represents the first ADC approved by the US Food and Drug Administration for the treatment of recurrent or metastatic CC with disease progression on or after chemotherapy. In phase I–III published trials, TV has already demonstrated an advantage in terms of objective response rate (17.8%–54.4%) and progression-free survival (3.1–6.9 months) in patients who progressed to the first-line standard therapy. Data concerning the addition of TV to platinum/pembrolizumab first-line chemotherapy are still under analysis and strongly expected. However, several questions are still unresolved: (1) the identification of the most suitable timing for ADCs administration in the treatment sequence of advanced/recurrent CC; (2) the evaluation of combination therapies as a tool to minimize the emergence of resistant clones and to enhance overall effectiveness; and (3) the assessment of tolerability and correct management of special toxicities (e.g. ocular and neurological adverse events). In the near future, an improvement in patient selection via biomarker-driven strategies should be crucial for optimizing both treatment benefits and maintaining an acceptable toxicity profile. [ABSTRACT FROM AUTHOR]
- Abstract:
Copyright of Therapeutic Advances in Medical Oncology is the property of Sage Publications Inc. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
No Comments.